Pharmacology of 5-Fluorouracil

Introduction/Overview

5-Fluorouracil (5-FU) represents a cornerstone of cytotoxic chemotherapy, belonging to the antimetabolite class of agents. Since its clinical introduction in the 1950s following the observation that rat hepatomas utilized uracil more rapidly than normal tissues, 5-FU has maintained a pivotal role in the systemic treatment of numerous solid malignancies. Its development marked a significant advancement in rational drug design, exploiting biochemical differences between normal and neoplastic cells. The drug’s enduring clinical relevance is underscored by its inclusion in first-line regimens for colorectal, gastric, breast, pancreatic, and head and neck cancers, often forming the backbone of combination chemotherapy protocols such as FOLFOX, FOLFIRI, and DCF. Understanding the pharmacology of 5-FU is essential for clinicians to optimize therapeutic efficacy while managing its complex and potentially severe toxicities.

Learning Objectives

• Describe the biochemical mechanism of action of 5-fluorouracil, including its activation to cytotoxic nucleotides and its primary inhibition of thymidylate synthase.
• Outline the pharmacokinetic profile of 5-FU, including routes of administration, metabolic pathways, and factors contributing to its variable interpatient disposition.
• Identify the major therapeutic indications for 5-FU, both as monotherapy and within standard combination regimens for specific malignancies.
• Recognize the spectrum of adverse effects associated with 5-FU therapy, from common mucositis and myelosuppression to rare but life-threatening toxicities like coronary vasospasm.
• Analyze special considerations for 5-FU use, including the impact of pharmacogenomics (DPD deficiency), organ dysfunction, and significant drug interactions.

Classification

5-Fluorouracil is systematically classified within several overlapping pharmacological and chemical hierarchies. Its primary therapeutic classification is as an antimetabolite chemotherapeutic agent. More specifically, it is a fluoropyrimidine analog, a subclass of antimetabolites designed to mimic the natural pyrimidine bases uracil and thymine. From a chemical perspective, 5-FU is a halogenated pyrimidine, where a fluorine atom substitutes for the hydrogen at the 5-carbon position of the uracil ring. This single atomic substitution is responsible for its profound biological activity. The drug is also categorized as a cell cycle-specific agent, with its primary cytotoxic effects exerted during the S-phase (DNA synthesis phase) of the cell cycle. Furthermore, oral prodrugs of 5-FU, such as capecitabine and tegafur, are also classified within the same therapeutic category, as they are enzymatically converted to 5-FU in vivo.

Mechanism of Action

The cytotoxicity of 5-fluorouracil is not mediated by a single mechanism but rather through the disruption of multiple critical biochemical pathways essential for DNA and RNA synthesis. Its action is dependent upon intracellular activation to cytotoxic nucleotide forms, which then interfere with normal nucleotide metabolism.

Metabolic Activation and Anabolism

5-FU itself is a prodrug requiring enzymatic conversion to active metabolites. The primary activation pathway involves conversion to fluorouridine monophosphate (FUMP). This can occur via two major routes: 1) the orotate phosphoribosyltransferase (OPRT) pathway, using phosphoribosyl pyrophosphate (PRPP), and 2) a sequential pathway involving uridine phosphorylase and uridine kinase. FUMP is subsequently phosphorylated to fluorouridine diphosphate (FUDP) and triphosphate (FUTP). FUTP can be incorporated into RNA in place of uridine triphosphate (UTP), leading to dysfunctional RNA processing and translation. Alternatively, FUDP can be reduced by ribonucleotide reductase to fluorodeoxyuridine diphosphate (FdUDP) and then to fluorodeoxyuridine monophosphate (FdUMP), the critical metabolite responsible for inhibiting thymidylate synthase.

Inhibition of Thymidylate Synthase

The most significant mechanism of action for 5-FU’s antiproliferative effect, particularly in solid tumors, is the inhibition of thymidylate synthase (TS). FdUMP forms a stable, covalent ternary complex with TS and the folate cofactor, 5,10-methylenetetrahydrofolate. This complex irreversibly inhibits TS, the enzyme responsible for catalyzing the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). dTMP is a necessary precursor for DNA synthesis. Inhibition of TS results in “thymineless death,” a condition characterized by the depletion of intracellular thymidine triphosphate (dTTP) pools, leading to impaired DNA synthesis, DNA strand breaks, and the initiation of apoptosis. The stability and efficacy of this inhibition are potentiated by the co-administration of leucovorin (folinic acid), which increases intracellular reduced folate pools, thereby stabilizing the ternary complex.

Incorporation into Nucleic Acids

Incorporation of 5-FU metabolites into both RNA and DNA contributes to its cytotoxicity. As mentioned, FUTP incorporation into RNA disrupts normal RNA function, affecting the processing of messenger RNA, transfer RNA, and ribosomal RNA. This interference with post-transcriptional modification and translation may contribute to early cytotoxic effects, including mucositis. Furthermore, a minor pathway involves the conversion of FdUMP to fluorodeoxyuridine triphosphate (FdUTP), which can be misincorporated into DNA. While this occurs less frequently, it contributes to DNA damage. Cellular repair mechanisms may excise these fraudulent bases, but subsequent repair synthesis can be futile in the setting of dTTP depletion, exacerbating DNA damage.

Cellular Consequences and Resistance Mechanisms

The collective biochemical insults lead to cell cycle arrest, primarily in S-phase, and the activation of apoptotic pathways. Cellular resistance to 5-FU can arise through multiple mechanisms. These include decreased activation of the drug (low expression of activating enzymes like OPRT), increased catabolism (high levels of dihydropyrimidine dehydrogenase, DPD), alterations in the target enzyme thymidylate synthase (gene amplification or mutations leading to over-expression or reduced binding affinity), and enhanced salvage pathways (increased thymidine kinase activity). An understanding of these resistance pathways informs the use of 5-FU in combination with other agents and the development of strategies to overcome resistance.

Pharmacokinetics

The pharmacokinetics of 5-fluorouracil are characterized by high interpatient variability, non-linear kinetics at higher doses, and a strong dependence on the route of administration. This variability is a major determinant of both efficacy and toxicity, underscoring the importance of therapeutic drug monitoring in some clinical contexts.

Absorption

Oral bioavailability of 5-FU is erratic and incomplete, typically ranging from 0 to 80%, due to extensive and variable first-pass metabolism by dihydropyrimidine dehydrogenase (DPD) in the intestinal mucosa and liver. Consequently, 5-FU is almost exclusively administered via parenteral routes. The two primary methods are intravenous bolus injection and continuous intravenous infusion. Bolus administration results in high peak plasma concentrations (C_max) but a short plasma half-life. Continuous infusion provides a sustained, steady-state plasma concentration (C_ss), which is often associated with a different toxicity profile and, in some malignancies, improved efficacy. Prodrugs like capecitabine were developed specifically to provide reliable oral delivery, as they are absorbed intact and undergo sequential enzymatic conversion to 5-FU, primarily within tumor tissue.

Distribution

Following intravenous administration, 5-FU distributes rapidly throughout total body water. It readily crosses the blood-brain barrier, with cerebrospinal fluid concentrations reaching approximately 10-20% of plasma levels. The volume of distribution is approximately 0.2 to 0.4 L/kg, suggesting distribution into both extracellular and intracellular compartments. Protein binding is negligible (less than 10%), meaning the majority of the drug in plasma is in the pharmacologically active, unbound form. The drug distributes into third-space fluid collections, such as ascites or pleural effusions, which can act as reservoirs and prolong exposure, potentially increasing toxicity.

Metabolism

Metabolism is the dominant route of elimination for 5-FU and is the primary source of its pharmacokinetic variability. Over 80% of an administered dose is catabolized in the liver and, to a lesser extent, in extrahepatic tissues like the intestinal mucosa. The rate-limiting step is catalyzed by dihydropyrimidine dehydrogenase (DPD), which reduces 5-FU to dihydrofluorouracil (DHFU). This inactive metabolite is then further degraded to α-fluoro-β-ureidopropionic acid (FUPA) and finally to α-fluoro-β-alanine (FBAL), which is renally excreted. Genetic polymorphisms leading to DPD deficiency result in profoundly reduced catabolic capacity, causing severe and potentially fatal toxicity (e.g., grade 4 myelosuppression, neurotoxicity, gastrointestinal necrosis) from standard doses. Only a small fraction (less than 20%) of the dose undergoes the anabolic pathways described in the mechanism of action section to form the active nucleotides.

Excretion

Renal excretion of unchanged 5-FU is minimal, accounting for less than 10% of the administered dose. The primary excretory products are the catabolites, with approximately 60-90% of the dose recovered in urine as FBAL and other metabolites within 24 hours. A small percentage (less than 10%) is excreted via the lungs as carbon dioxide, a product of the complete catabolic breakdown of the pyrimidine ring. The elimination half-life (t_1/2) is short, ranging from 8 to 20 minutes following a bolus injection. However, due to saturation of the DPD enzyme at higher doses or in DPD-deficient patients, the kinetics can shift from first-order to zero-order, leading to a prolonged half-life and disproportionate increases in systemic exposure (AUC). Clearance is high, typically 0.5 to 2.0 L/min/m², and is directly correlated with DPD activity.

Therapeutic Uses/Clinical Applications

5-Fluorouracil possesses a broad spectrum of activity against solid tumors and is rarely used as a single agent in modern oncology. Its efficacy is significantly enhanced when used in combination with other chemotherapeutic agents, biologics, and radiation therapy.

Approved Indications

• Colorectal Cancer: This remains the most prominent indication. 5-FU is the foundational component of standard adjuvant and palliative regimens. Common combinations include:
  • FOLFOX: 5-FU, leucovorin, and oxaliplatin.
  • FOLFIRI: 5-FU, leucovorin, and irinotecan.
  • CAPOX: Capecitabine (oral 5-FU prodrug) and oxaliplatin.

  It is used for stages II-IV disease.

• Breast Cancer: Used in combination regimens for both early-stage and metastatic disease. A common regimen is CMF (cyclophosphamide, methotrexate, and 5-FU), though taxane-based regimens are now more prevalent. Capecitabine is frequently used for metastatic HER2-negative disease, particularly after anthracycline and taxane failure.
• Gastroesophageal Cancers: A key component of perioperative and palliative regimens, such as DCF (docetaxel, cisplatin, and 5-FU) or its modifications, and FLOT (5-FU, leucovorin, oxaliplatin, docetaxel).
• Pancreatic Cancer: Used in the adjuvant setting (e.g., with leucovorin, irinotecan, and oxaliplatin in the FOLFIRINOX regimen, which is highly active but toxic) and for advanced disease.
• Head and Neck Squamous Cell Carcinoma: Often administered as a continuous infusion concurrently with radiation therapy (chemoradiation) for locally advanced disease, or in combination with cisplatin and a taxoid.
• Topical Formulations: 5% cream or solution is approved for the topical treatment of actinic keratoses and superficial basal cell carcinomas.

Off-Label and Other Uses

5-FU is used off-label in several other contexts, often based on clinical trial evidence. These include anal carcinoma (with mitomycin and radiation), hepatobiliary cancers, and as a radiosensitizer for other malignancies. Intralesional injection has been used for keratoacanthomas. Furthermore, 5-FU is frequently added to combination regimens for other adenocarcinomas of unknown primary origin.

Adverse Effects

The adverse effect profile of 5-fluorouracil is extensive and can affect nearly every organ system. The severity and pattern of toxicity are often influenced by the schedule of administration (bolus vs. infusion).

Common Side Effects

• Myelosuppression: Neutropenia is the dose-limiting toxicity for bolus schedules, typically occurring 7-14 days after administration, with recovery by days 21-28. Thrombocytopenia and anemia also occur but are generally less severe.
• Mucositis/Stomatitis: Inflammation and ulceration of the oral and gastrointestinal mucosa is a hallmark toxicity, particularly with continuous infusion schedules. It can lead to pain, dysphagia, diarrhea, and risk of superinfection.
• Gastrointestinal Effects: Diarrhea is common and can be severe, leading to dehydration and electrolyte imbalances. Nausea and vomiting are frequent but are usually manageable with modern antiemetics.
• Dermatological Effects: Hand-foot syndrome (palmar-plantar erythrodysesthesia) is characterized by painful erythema, swelling, and desquamation of the palms and soles, commonly associated with continuous infusion or capecitabine. Alopecia, photosensitivity, and hyperpigmentation are also observed.
• Neurological Effects: Acute cerebellar dysfunction (ataxia, nystagmus, dysarthria) is an uncommon but characteristic toxicity, often associated with high plasma concentrations in patients with DPD deficiency.

Serious/Rare Adverse Reactions

• Cardiotoxicity: Manifestations include angina-like chest pain, myocardial infarction, arrhythmias, and cardiomyopathy. Symptoms often occur within 72 hours of infusion and are thought to be due to coronary vasospasm. Pre-existing cardiac disease is a risk factor.
• Hyperammonemic Encephalopathy: A rare but acute neurotoxicity presenting with confusion, seizures, and coma, associated with markedly elevated serum ammonia levels.
• Severe Diarrhea and Dehydration: Can progress to life-threatening volume depletion, renal failure, and electrolyte disturbances.
• Myelosuppression with Sepsis: Profound neutropenia can lead to febrile neutropenia and fatal infections.
• Gastrointestinal Perforation or Bleeding: Severe mucositis may rarely lead to these catastrophic events.

Black Box Warnings

5-Fluorouracil carries a black box warning from the U.S. Food and Drug Administration related to its administration. The warning emphasizes that the drug should be administered only by or under the supervision of a physician experienced in cancer chemotherapy. It further highlights that patients should be hospitalized during their initial course of therapy due to the high risk of severe toxic reactions, which may be fatal. These toxicities include myelosuppression, infections, gastrointestinal ulceration and bleeding, and other severe side effects. This warning underscores the narrow therapeutic index and the necessity for meticulous patient monitoring.

Drug Interactions

5-Fluorouracil participates in several clinically significant pharmacokinetic and pharmacodynamic drug interactions that can alter its efficacy or toxicity profile.

Major Drug-Drug Interactions

• Leucovorin (Folinic Acid): This is a synergistic interaction, not an adverse one. Leucovorin potentiates the cytotoxicity of 5-FU by stabilizing the ternary complex between FdUMP and thymidylate synthase, increasing the degree and duration of TS inhibition.
• Methotrexate: The sequence of administration is critical. Methotrexate given before 5-FU can enhance 5-FU activation by increasing PRPP pools. However, if 5-FU is given before methotrexate, it may antagonize methotrexate’s effect by inhibiting purine synthesis. A typical interval is 24 hours between methotrexate and 5-FU administration.
• Cimetidine: This H2-receptor antagonist may inhibit the hepatic metabolism of 5-FU by interfering with the cytochrome P450 system involved in some catabolic steps, potentially leading to increased 5-FU plasma levels and toxicity.
• Warfarin: 5-FU may potentiate the anticoagulant effect of warfarin, possibly by inhibiting its metabolic clearance. Prothrombin time (INR) requires close monitoring in patients on concomitant therapy.
• Brivudine, Sorivudine: These antiviral drugs are potent, irreversible inhibitors of DPD. Concomitant use with 5-FU or its prodrugs can cause fatal accumulation of 5-FU due to complete blockade of its primary catabolic pathway. This combination is absolutely contraindicated.
• Allopurinol: May theoretically interfere with the activation of 5-FU, though evidence for clinical antagonism is mixed. It is sometimes used to mitigate 5-FU-induced hyperuricemia.
• Live Vaccines: Administration is contraindicated due to the immunosuppressive effects of 5-FU, which can lead to vaccine-induced infection.

Contraindications

Absolute contraindications to 5-fluorouracil therapy include known severe hypersensitivity to the drug or its components, severe bone marrow suppression (e.g., baseline neutrophil count < 1.5 × 10⁹/L, platelets < 100 × 10⁹/L), and pregnancy. It is also contraindicated in patients with severe, uncontrolled infections. As noted, concomitant use with brivudine or sorivudine is absolutely contraindicated. Known complete deficiency of dihydropyrimidine dehydrogenase (DPD) is a strong relative contraindication to standard dosing, though dose-reduced therapy may be considered with extreme caution and plasma level monitoring.

Special Considerations

Use in Pregnancy and Lactation

5-Fluorouracil is classified as Pregnancy Category D (positive evidence of human fetal risk). The drug is teratogenic and embryotoxic. It can cause fetal malformations, particularly when administered during the first trimester. Use during pregnancy is only justified if the potential benefit to the mother outweighs the significant risk to the fetus. Women of childbearing potential should be advised to use effective contraception during and for at least 6 months after therapy. 5-FU is excreted into breast milk, and due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during treatment.

Pediatric and Geriatric Considerations

Safety and effectiveness in pediatric patients have not been firmly established, though it is used in certain pediatric solid tumors. Geriatric patients may be at increased risk for severe adverse effects, including myelosuppression, gastrointestinal toxicity, and cardiotoxicity, due to decreased renal or hepatic function and increased prevalence of comorbidities. Dose selection for an elderly patient should be cautious, often starting at the lower end of the dosing range, with careful monitoring of hematological and clinical parameters.

Renal and Hepatic Impairment

Formal dosing guidelines for renal impairment are not well-established, as renal excretion of unchanged drug is minimal. However, the terminal catabolite, FBAL, is renally excreted. In severe renal impairment (creatinine clearance < 30 mL/min), accumulation of FBAL is possible, though its clinical significance is unclear. Caution is advised, and consideration may be given to dose reduction or increased monitoring. Hepatic impairment is a more significant concern. Since DPD-mediated catabolism primarily occurs in the liver, patients with moderate to severe hepatic dysfunction may have reduced 5-FU clearance, leading to increased systemic exposure and toxicity. Dose reduction is generally recommended in patients with significant liver impairment, such as those with bilirubin levels > 1.5 times the upper limit of normal.

Pharmacogenomic Considerations

Genetic polymorphisms in the DPYD gene, which encodes dihydropyrimidine dehydrogenase, are the most critical pharmacogenomic factor. Partial (heterozygous) or complete (homozygous) DPD deficiency occurs in approximately 3-5% and 0.1% of the population, respectively. Patients with DPD deficiency are at extremely high risk for severe, life-threatening toxicity from standard doses of 5-FU or capecitabine. Pretreatment screening for DPD activity (via phenotypic measurement of uracil levels) or genotyping for common DPYD variants (e.g., *2A, *13) is increasingly recommended to guide initial dose reduction or drug selection.

Summary/Key Points

• 5-Fluorouracil is a fluoropyrimidine antimetabolite that requires intracellular activation to exert cytotoxicity primarily through inhibition of thymidylate synthase and incorporation into RNA and DNA.
• Its pharmacokinetics are highly variable, dominated by catabolism via dihydropyrimidine dehydrogenase (DPD), and are schedule-dependent, with continuous infusion often yielding a different efficacy-toxicity profile compared to bolus administration.
• It is a foundational drug in the treatment of gastrointestinal (colorectal, gastric, pancreatic), breast, and head and neck cancers, almost always used in combination with other agents like leucovorin, oxaliplatin, or irinotecan.
• The adverse effect profile is broad, with myelosuppression (bolus) and mucositis/diarrhea (infusion) being dose-limiting. Serious toxicities include cardiotoxicity, neurotoxicity, and hyperammonemic encephalopathy.
• Genetic deficiency in DPD is a major risk factor for severe toxicity. Significant drug interactions exist, most notably the contraindicated combination with DPD-inhibiting antivirals like brivudine.
• Special caution is required in pregnancy, lactation, elderly patients, and those with hepatic impairment. Pharmacogenomic testing for DPD status is becoming a standard consideration prior to initiating therapy.

Clinical Pearls

• The co-administration of leucovorin is not a “rescue” agent (as with methotrexate) but a biochemical modulator that enhances 5-FU’s antitumor activity and toxicity.
• Cardiac chest pain during or shortly after infusion should be treated as possible 5-FU-induced coronary vasospasm; cessation of infusion and administration of nitrates and calcium channel blockers may be required.
• Early-onset severe toxicity (e.g., mucositis, diarrhea, neutropenia within the first 1-2 cycles) should raise immediate suspicion for DPD deficiency.
• Topical 5-FU cream for actinic keratosis can cause significant local inflammation; patients should be counseled that this is an expected therapeutic effect, not an allergic reaction.
• When switching from intravenous 5-FU to oral capecitabine, clinicians must account for the near-continuous exposure provided by the oral prodrug, which mimics a prolonged infusion.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.